nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—PRKD1—head—pharynx cancer	0.00292	0.00497	CbGeAlD
Crizotinib—CDK7—lymphoid tissue—pharynx cancer	0.00291	0.00496	CbGeAlD
Crizotinib—SIK2—head—pharynx cancer	0.00288	0.00491	CbGeAlD
Crizotinib—FER—trachea—pharynx cancer	0.00283	0.00482	CbGeAlD
Crizotinib—RIPK2—saliva-secreting gland—pharynx cancer	0.00282	0.0048	CbGeAlD
Crizotinib—TNK1—trachea—pharynx cancer	0.0028	0.00477	CbGeAlD
Crizotinib—TBK1—parotid gland—pharynx cancer	0.00273	0.00465	CbGeAlD
Crizotinib—TYK2—parotid gland—pharynx cancer	0.00271	0.00462	CbGeAlD
Crizotinib—LTK—head—pharynx cancer	0.00268	0.00456	CbGeAlD
Crizotinib—EPHA4—brainstem—pharynx cancer	0.00267	0.00454	CbGeAlD
Crizotinib—JAK3—lymphoid tissue—pharynx cancer	0.00265	0.00452	CbGeAlD
Crizotinib—RPS6KB1—parotid gland—pharynx cancer	0.00263	0.00448	CbGeAlD
Crizotinib—PLK4—lymphoid tissue—pharynx cancer	0.00262	0.00447	CbGeAlD
Crizotinib—TBK1—saliva-secreting gland—pharynx cancer	0.00261	0.00446	CbGeAlD
Crizotinib—PTK2—saliva-secreting gland—pharynx cancer	0.00261	0.00446	CbGeAlD
Crizotinib—STK4—lymphoid tissue—pharynx cancer	0.00261	0.00444	CbGeAlD
Crizotinib—TYK2—saliva-secreting gland—pharynx cancer	0.0026	0.00443	CbGeAlD
Crizotinib—MAPK7—head—pharynx cancer	0.00259	0.00442	CbGeAlD
Crizotinib—TXK—head—pharynx cancer	0.00259	0.00442	CbGeAlD
Crizotinib—EPHA8—head—pharynx cancer	0.00257	0.00437	CbGeAlD
Crizotinib—TESK1—trachea—pharynx cancer	0.00255	0.00435	CbGeAlD
Crizotinib—RPS6KB1—saliva-secreting gland—pharynx cancer	0.00251	0.00429	CbGeAlD
Crizotinib—SLK—parotid gland—pharynx cancer	0.0025	0.00426	CbGeAlD
Crizotinib—EPHB4—parotid gland—pharynx cancer	0.00248	0.00423	CbGeAlD
Crizotinib—FER—lymphoid tissue—pharynx cancer	0.00246	0.0042	CbGeAlD
Crizotinib—TYRO3—lymphoid tissue—pharynx cancer	0.00246	0.0042	CbGeAlD
Crizotinib—ALK—lymphoid tissue—pharynx cancer	0.00246	0.0042	CbGeAlD
Crizotinib—RIPK2—epithelium—pharynx cancer	0.00246	0.00419	CbGeAlD
Crizotinib—LYN—lymphoid tissue—pharynx cancer	0.00245	0.00418	CbGeAlD
Crizotinib—EPHA2—parotid gland—pharynx cancer	0.00244	0.00415	CbGeAlD
Crizotinib—LIMK2—trachea—pharynx cancer	0.00243	0.00414	CbGeAlD
Crizotinib—MET—head—pharynx cancer	0.00243	0.00413	CbGeAlD
Crizotinib—NUAK2—trachea—pharynx cancer	0.00242	0.00413	CbGeAlD
Crizotinib—MAP4K1—lymphoid tissue—pharynx cancer	0.00241	0.00411	CbGeAlD
Crizotinib—ACVR1—trachea—pharynx cancer	0.0024	0.0041	CbGeAlD
Crizotinib—SLK—saliva-secreting gland—pharynx cancer	0.0024	0.00408	CbGeAlD
Crizotinib—DCLK1—spinal cord—pharynx cancer	0.00239	0.00408	CbGeAlD
Crizotinib—EPHB4—saliva-secreting gland—pharynx cancer	0.00238	0.00405	CbGeAlD
Crizotinib—MAP3K3—parotid gland—pharynx cancer	0.00238	0.00405	CbGeAlD
Crizotinib—MAP4K5—parotid gland—pharynx cancer	0.00238	0.00405	CbGeAlD
Crizotinib—IGF1R—lymphoid tissue—pharynx cancer	0.00237	0.00403	CbGeAlD
Crizotinib—CDK7—head—pharynx cancer	0.00235	0.004	CbGeAlD
Crizotinib—EPHA2—saliva-secreting gland—pharynx cancer	0.00233	0.00398	CbGeAlD
Crizotinib—MAP4K2—lymphoid tissue—pharynx cancer	0.00233	0.00398	CbGeAlD
Crizotinib—PTK2—epithelium—pharynx cancer	0.00228	0.00389	CbGeAlD
Crizotinib—MAP4K5—saliva-secreting gland—pharynx cancer	0.00228	0.00388	CbGeAlD
Crizotinib—MAP3K3—saliva-secreting gland—pharynx cancer	0.00228	0.00388	CbGeAlD
Crizotinib—EPHB6—parotid gland—pharynx cancer	0.00227	0.00387	CbGeAlD
Crizotinib—AURKA—lymphoid tissue—pharynx cancer	0.00224	0.00382	CbGeAlD
Crizotinib—EPHA3—head—pharynx cancer	0.00224	0.00382	CbGeAlD
Crizotinib—ACVR1B—head—pharynx cancer	0.00224	0.00382	CbGeAlD
Crizotinib—NEK9—lymph node—pharynx cancer	0.00224	0.00382	CbGeAlD
Crizotinib—EPHA5—spinal cord—pharynx cancer	0.00223	0.00381	CbGeAlD
Crizotinib—FER—spinal cord—pharynx cancer	0.00223	0.00381	CbGeAlD
Crizotinib—TYRO3—spinal cord—pharynx cancer	0.00223	0.00381	CbGeAlD
Crizotinib—YES1—parotid gland—pharynx cancer	0.0022	0.00374	CbGeAlD
Crizotinib—RPS6KB1—epithelium—pharynx cancer	0.00219	0.00374	CbGeAlD
Crizotinib—EPHB6—saliva-secreting gland—pharynx cancer	0.00218	0.00371	CbGeAlD
Crizotinib—RIPK2—trachea—pharynx cancer	0.00217	0.0037	CbGeAlD
Crizotinib—TAOK3—parotid gland—pharynx cancer	0.00217	0.00369	CbGeAlD
Crizotinib—MERTK—lymphoid tissue—pharynx cancer	0.00216	0.00369	CbGeAlD
Crizotinib—EPHA6—head—pharynx cancer	0.00214	0.00365	CbGeAlD
Crizotinib—JAK3—head—pharynx cancer	0.00214	0.00365	CbGeAlD
Crizotinib—DCLK1—head—pharynx cancer	0.00213	0.00362	CbGeAlD
Crizotinib—LIMK2—lymphoid tissue—pharynx cancer	0.00212	0.00361	CbGeAlD
Crizotinib—YES1—saliva-secreting gland—pharynx cancer	0.0021	0.00358	CbGeAlD
Crizotinib—STK4—head—pharynx cancer	0.0021	0.00358	CbGeAlD
Crizotinib—EPHA4—trachea—pharynx cancer	0.0021	0.00358	CbGeAlD
Crizotinib—FLT3—lymphoid tissue—pharynx cancer	0.00209	0.00357	CbGeAlD
Crizotinib—TAOK3—saliva-secreting gland—pharynx cancer	0.00208	0.00354	CbGeAlD
Crizotinib—EPHB4—epithelium—pharynx cancer	0.00208	0.00354	CbGeAlD
Crizotinib—JAK2—epithelium—pharynx cancer	0.00206	0.00351	CbGeAlD
Crizotinib—PRKD1—lymph node—pharynx cancer	0.00204	0.00348	CbGeAlD
Crizotinib—EPHA2—epithelium—pharynx cancer	0.00204	0.00347	CbGeAlD
Crizotinib—TAOK3—brainstem—pharynx cancer	0.00203	0.00347	CbGeAlD
Crizotinib—TESK1—spinal cord—pharynx cancer	0.00202	0.00344	CbGeAlD
Crizotinib—TBK1—trachea—pharynx cancer	0.00202	0.00344	CbGeAlD
Crizotinib—PTK2—trachea—pharynx cancer	0.00202	0.00344	CbGeAlD
Crizotinib—LIMK1—lymph node—pharynx cancer	0.00202	0.00344	CbGeAlD
Crizotinib—TYK2—trachea—pharynx cancer	0.002	0.00341	CbGeAlD
Crizotinib—TEK—epithelium—pharynx cancer	0.00199	0.00339	CbGeAlD
Crizotinib—EPHA5—head—pharynx cancer	0.00198	0.00338	CbGeAlD
Crizotinib—FER—head—pharynx cancer	0.00198	0.00338	CbGeAlD
Crizotinib—ALK—head—pharynx cancer	0.00198	0.00338	CbGeAlD
Crizotinib—TYRO3—head—pharynx cancer	0.00198	0.00338	CbGeAlD
Crizotinib—LYN—head—pharynx cancer	0.00197	0.00336	CbGeAlD
Crizotinib—PRKD3—lymph node—pharynx cancer	0.00196	0.00335	CbGeAlD
Crizotinib—BMPR1B—head—pharynx cancer	0.00194	0.00331	CbGeAlD
Crizotinib—MAP3K19—head—pharynx cancer	0.00194	0.00331	CbGeAlD
Crizotinib—RPS6KB1—trachea—pharynx cancer	0.00194	0.00331	CbGeAlD
Crizotinib—LCK—trachea—pharynx cancer	0.00193	0.00329	CbGeAlD
Crizotinib—AXL—trachea—pharynx cancer	0.00192	0.00327	CbGeAlD
Crizotinib—LIMK2—spinal cord—pharynx cancer	0.00192	0.00327	CbGeAlD
Crizotinib—DSTYK—lymph node—pharynx cancer	0.00192	0.00327	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—pharynx cancer	0.00191	0.00325	CbGeAlD
Crizotinib—TNK2—head—pharynx cancer	0.00191	0.00325	CbGeAlD
Crizotinib—IGF1R—head—pharynx cancer	0.00191	0.00325	CbGeAlD
Crizotinib—MAP3K12—spinal cord—pharynx cancer	0.0019	0.00324	CbGeAlD
Crizotinib—ACVR1—spinal cord—pharynx cancer	0.0019	0.00324	CbGeAlD
Crizotinib—BLK—lymph node—pharynx cancer	0.00189	0.00323	CbGeAlD
Crizotinib—LTK—lymph node—pharynx cancer	0.00187	0.00319	CbGeAlD
Crizotinib—CASK—lymph node—pharynx cancer	0.00187	0.00319	CbGeAlD
Crizotinib—STK3—head—pharynx cancer	0.00185	0.00316	CbGeAlD
Crizotinib—TIE1—head—pharynx cancer	0.00185	0.00316	CbGeAlD
Crizotinib—SLK—trachea—pharynx cancer	0.00185	0.00315	CbGeAlD
Crizotinib—EPHB4—trachea—pharynx cancer	0.00183	0.00313	CbGeAlD
Crizotinib—JAK2—trachea—pharynx cancer	0.00182	0.00311	CbGeAlD
Crizotinib—MAPK7—lymph node—pharynx cancer	0.00181	0.00309	CbGeAlD
Crizotinib—TXK—lymph node—pharynx cancer	0.00181	0.00309	CbGeAlD
Crizotinib—AURKA—head—pharynx cancer	0.00181	0.00308	CbGeAlD
Crizotinib—EPHA2—trachea—pharynx cancer	0.0018	0.00307	CbGeAlD
Crizotinib—FES—lymph node—pharynx cancer	0.0018	0.00306	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—pharynx cancer	0.00179	0.00306	CbGeAlD
Crizotinib—TESK1—head—pharynx cancer	0.00179	0.00306	CbGeAlD
Crizotinib—BMP2K—spinal cord—pharynx cancer	0.00179	0.00305	CbGeAlD
Crizotinib—SRC—epithelium—pharynx cancer	0.00176	0.00301	CbGeAlD
Crizotinib—MAP3K3—trachea—pharynx cancer	0.00176	0.00299	CbGeAlD
Crizotinib—MAP4K5—trachea—pharynx cancer	0.00176	0.00299	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—pharynx cancer	0.00176	0.00299	CbGeAlD
Crizotinib—PTK2—lymphoid tissue—pharynx cancer	0.00176	0.00299	CbGeAlD
Crizotinib—TYK2—lymphoid tissue—pharynx cancer	0.00174	0.00297	CbGeAlD
Crizotinib—MERTK—head—pharynx cancer	0.00174	0.00297	CbGeAlD
Crizotinib—RIPK2—spinal cord—pharynx cancer	0.00171	0.00292	CbGeAlD
Crizotinib—LIMK2—head—pharynx cancer	0.00171	0.00291	CbGeAlD
Crizotinib—MET—lymph node—pharynx cancer	0.0017	0.0029	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—pharynx cancer	0.00169	0.00288	CbGeAlD
Crizotinib—MAP3K12—head—pharynx cancer	0.00169	0.00288	CbGeAlD
Crizotinib—ACVR1—head—pharynx cancer	0.00169	0.00288	CbGeAlD
Crizotinib—FGR—lymphoid tissue—pharynx cancer	0.00168	0.00286	CbGeAlD
Crizotinib—EPHB6—trachea—pharynx cancer	0.00168	0.00286	CbGeAlD
Crizotinib—AXL—lymphoid tissue—pharynx cancer	0.00167	0.00285	CbGeAlD
Crizotinib—STK35—head—pharynx cancer	0.00165	0.00282	CbGeAlD
Crizotinib—CDK7—lymph node—pharynx cancer	0.00164	0.0028	CbGeAlD
Crizotinib—TAOK2—lymph node—pharynx cancer	0.00163	0.00278	CbGeAlD
Crizotinib—YES1—trachea—pharynx cancer	0.00162	0.00276	CbGeAlD
Crizotinib—TAOK3—trachea—pharynx cancer	0.0016	0.00273	CbGeAlD
Crizotinib—TBK1—spinal cord—pharynx cancer	0.00159	0.00271	CbGeAlD
Crizotinib—PTK2—spinal cord—pharynx cancer	0.00159	0.00271	CbGeAlD
Crizotinib—BMP2K—head—pharynx cancer	0.00159	0.00271	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—pharynx cancer	0.00159	0.00271	CbGeAlD
Crizotinib—TYK2—spinal cord—pharynx cancer	0.00158	0.0027	CbGeAlD
Crizotinib—ACVR1B—lymph node—pharynx cancer	0.00157	0.00268	CbGeAlD
Crizotinib—EPHA3—lymph node—pharynx cancer	0.00157	0.00268	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—pharynx cancer	0.00157	0.00267	CbGeAlD
Crizotinib—PTK2B—head—pharynx cancer	0.00154	0.00262	CbGeAlD
Crizotinib—RPS6KB1—spinal cord—pharynx cancer	0.00153	0.00261	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—pharynx cancer	0.00153	0.00261	CbGeAlD
Crizotinib—TEK—lymphoid tissue—pharynx cancer	0.00153	0.00261	CbGeAlD
Crizotinib—RIPK2—head—pharynx cancer	0.00152	0.0026	CbGeAlD
Crizotinib—AXL—spinal cord—pharynx cancer	0.00152	0.00258	CbGeAlD
Crizotinib—ABL1—parotid gland—pharynx cancer	0.0015	0.00255	CbGeAlD
Crizotinib—JAK3—lymph node—pharynx cancer	0.0015	0.00255	CbGeAlD
Crizotinib—DCLK1—lymph node—pharynx cancer	0.00149	0.00254	CbGeAlD
Crizotinib—PLK4—lymph node—pharynx cancer	0.00148	0.00252	CbGeAlD
Crizotinib—EPHA4—head—pharynx cancer	0.00147	0.00251	CbGeAlD
Crizotinib—STK4—lymph node—pharynx cancer	0.00147	0.00251	CbGeAlD
Crizotinib—SLK—spinal cord—pharynx cancer	0.00146	0.00249	CbGeAlD
Crizotinib—EPHB4—spinal cord—pharynx cancer	0.00145	0.00247	CbGeAlD
Crizotinib—MAP3K2—head—pharynx cancer	0.00144	0.00246	CbGeAlD
Crizotinib—JAK2—spinal cord—pharynx cancer	0.00144	0.00245	CbGeAlD
Crizotinib—ABL1—saliva-secreting gland—pharynx cancer	0.00144	0.00245	CbGeAlD
Crizotinib—PTK2—head—pharynx cancer	0.00142	0.00241	CbGeAlD
Crizotinib—TBK1—head—pharynx cancer	0.00142	0.00241	CbGeAlD
Crizotinib—YES1—lymphoid tissue—pharynx cancer	0.00141	0.00241	CbGeAlD
Crizotinib—ABL1—brainstem—pharynx cancer	0.00141	0.0024	CbGeAlD
Crizotinib—TYK2—head—pharynx cancer	0.00141	0.0024	CbGeAlD
Crizotinib—CSF1R—trachea—pharynx cancer	0.0014	0.00239	CbGeAlD
Crizotinib—STK10—lymphoid tissue—pharynx cancer	0.0014	0.00239	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—pharynx cancer	0.00139	0.00238	CbGeAlD
Crizotinib—FER—lymph node—pharynx cancer	0.00139	0.00237	CbGeAlD
Crizotinib—ALK—lymph node—pharynx cancer	0.00139	0.00237	CbGeAlD
Crizotinib—TEK—spinal cord—pharynx cancer	0.00139	0.00236	CbGeAlD
Crizotinib—MAP4K5—spinal cord—pharynx cancer	0.00139	0.00236	CbGeAlD
Crizotinib—MAP3K3—spinal cord—pharynx cancer	0.00139	0.00236	CbGeAlD
Crizotinib—TNK1—lymph node—pharynx cancer	0.00138	0.00234	CbGeAlD
Crizotinib—BMPR1B—lymph node—pharynx cancer	0.00136	0.00232	CbGeAlD
Crizotinib—MAP4K1—lymph node—pharynx cancer	0.00136	0.00232	CbGeAlD
Crizotinib—RPS6KB1—head—pharynx cancer	0.00136	0.00232	CbGeAlD
Crizotinib—SRC—lymphoid tissue—pharynx cancer	0.00136	0.00232	CbGeAlD
Crizotinib—FGR—head—pharynx cancer	0.00135	0.00231	CbGeAlD
Crizotinib—AXL—head—pharynx cancer	0.00135	0.0023	CbGeAlD
Crizotinib—IGF1R—lymph node—pharynx cancer	0.00133	0.00228	CbGeAlD
Crizotinib—TNK2—lymph node—pharynx cancer	0.00133	0.00228	CbGeAlD
Crizotinib—EPHB6—spinal cord—pharynx cancer	0.00133	0.00226	CbGeAlD
Crizotinib—MAP4K2—lymph node—pharynx cancer	0.00132	0.00224	CbGeAlD
Crizotinib—STK3—lymph node—pharynx cancer	0.0013	0.00221	CbGeAlD
Crizotinib—TIE1—lymph node—pharynx cancer	0.0013	0.00221	CbGeAlD
Crizotinib—YES1—spinal cord—pharynx cancer	0.00128	0.00218	CbGeAlD
Crizotinib—JAK2—head—pharynx cancer	0.00128	0.00218	CbGeAlD
Crizotinib—AURKA—lymph node—pharynx cancer	0.00127	0.00216	CbGeAlD
Crizotinib—TAOK3—spinal cord—pharynx cancer	0.00126	0.00216	CbGeAlD
Crizotinib—EPHA2—head—pharynx cancer	0.00126	0.00215	CbGeAlD
Crizotinib—TESK1—lymph node—pharynx cancer	0.00126	0.00214	CbGeAlD
Crizotinib—TEK—head—pharynx cancer	0.00123	0.0021	CbGeAlD
Crizotinib—MAP3K3—head—pharynx cancer	0.00123	0.0021	CbGeAlD
Crizotinib—MAP4K5—head—pharynx cancer	0.00123	0.0021	CbGeAlD
Crizotinib—SRC—spinal cord—pharynx cancer	0.00123	0.0021	CbGeAlD
Crizotinib—MERTK—lymph node—pharynx cancer	0.00122	0.00208	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—pharynx cancer	0.00122	0.00208	CbGeAlD
Crizotinib—LIMK2—lymph node—pharynx cancer	0.00119	0.00204	CbGeAlD
Crizotinib—NUAK2—lymph node—pharynx cancer	0.00119	0.00203	CbGeAlD
Crizotinib—MAP3K12—lymph node—pharynx cancer	0.00118	0.00201	CbGeAlD
Crizotinib—ACVR1—lymph node—pharynx cancer	0.00118	0.00201	CbGeAlD
Crizotinib—FLT3—lymph node—pharynx cancer	0.00118	0.00201	CbGeAlD
Crizotinib—EPHB6—head—pharynx cancer	0.00118	0.00201	CbGeAlD
Crizotinib—STK35—lymph node—pharynx cancer	0.00116	0.00197	CbGeAlD
Crizotinib—YES1—head—pharynx cancer	0.00114	0.00194	CbGeAlD
Crizotinib—ABL2—lymph node—pharynx cancer	0.00113	0.00192	CbGeAlD
Crizotinib—STK10—head—pharynx cancer	0.00113	0.00192	CbGeAlD
Crizotinib—TAOK3—head—pharynx cancer	0.00112	0.00192	CbGeAlD
Crizotinib—BMP2K—lymph node—pharynx cancer	0.00111	0.0019	CbGeAlD
Crizotinib—ABL1—trachea—pharynx cancer	0.00111	0.00189	CbGeAlD
Crizotinib—CSF1R—spinal cord—pharynx cancer	0.00111	0.00189	CbGeAlD
Crizotinib—SRC—head—pharynx cancer	0.00109	0.00187	CbGeAlD
Crizotinib—PTK2B—lymph node—pharynx cancer	0.00108	0.00183	CbGeAlD
Crizotinib—RIPK2—lymph node—pharynx cancer	0.00107	0.00182	CbGeAlD
Crizotinib—EPHA4—lymph node—pharynx cancer	0.00103	0.00176	CbGeAlD
Crizotinib—MAP3K2—lymph node—pharynx cancer	0.00101	0.00172	CbGeAlD
Crizotinib—TBK1—lymph node—pharynx cancer	0.000991	0.00169	CbGeAlD
Crizotinib—PTK2—lymph node—pharynx cancer	0.000991	0.00169	CbGeAlD
Crizotinib—TYK2—lymph node—pharynx cancer	0.000984	0.00168	CbGeAlD
Crizotinib—CSF1R—head—pharynx cancer	0.000983	0.00168	CbGeAlD
Crizotinib—IRAK1—lymph node—pharynx cancer	0.000971	0.00166	CbGeAlD
Crizotinib—ABL1—lymphoid tissue—pharynx cancer	0.000964	0.00164	CbGeAlD
Crizotinib—RPS6KB1—lymph node—pharynx cancer	0.000953	0.00162	CbGeAlD
Crizotinib—LCK—lymph node—pharynx cancer	0.000947	0.00161	CbGeAlD
Crizotinib—FGR—lymph node—pharynx cancer	0.000947	0.00161	CbGeAlD
Crizotinib—AXL—lymph node—pharynx cancer	0.000944	0.00161	CbGeAlD
Crizotinib—SLK—lymph node—pharynx cancer	0.000908	0.00155	CbGeAlD
Crizotinib—EPHB4—lymph node—pharynx cancer	0.000902	0.00154	CbGeAlD
Crizotinib—JAK2—lymph node—pharynx cancer	0.000895	0.00153	CbGeAlD
Crizotinib—EPHA2—lymph node—pharynx cancer	0.000885	0.00151	CbGeAlD
Crizotinib—ABL1—spinal cord—pharynx cancer	0.000874	0.00149	CbGeAlD
Crizotinib—MAP4K5—lymph node—pharynx cancer	0.000863	0.00147	CbGeAlD
Crizotinib—MAP3K3—lymph node—pharynx cancer	0.000863	0.00147	CbGeAlD
Crizotinib—TEK—lymph node—pharynx cancer	0.000863	0.00147	CbGeAlD
Crizotinib—EPHB6—lymph node—pharynx cancer	0.000825	0.00141	CbGeAlD
Crizotinib—YES1—lymph node—pharynx cancer	0.000797	0.00136	CbGeAlD
Crizotinib—STK10—lymph node—pharynx cancer	0.00079	0.00135	CbGeAlD
Crizotinib—TAOK3—lymph node—pharynx cancer	0.000787	0.00134	CbGeAlD
Crizotinib—ABL1—head—pharynx cancer	0.000777	0.00132	CbGeAlD
Crizotinib—SRC—lymph node—pharynx cancer	0.000767	0.00131	CbGeAlD
Crizotinib—CSF1R—lymph node—pharynx cancer	0.000688	0.00117	CbGeAlD
Crizotinib—ABL1—lymph node—pharynx cancer	0.000544	0.000927	CbGeAlD
Crizotinib—ABCB1—epithelium—pharynx cancer	0.000389	0.000664	CbGeAlD
Crizotinib—ABCB1—trachea—pharynx cancer	0.000344	0.000587	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—pharynx cancer	0.0003	0.000511	CbGeAlD
Crizotinib—ABCB1—spinal cord—pharynx cancer	0.000272	0.000463	CbGeAlD
Crizotinib—ABCB1—head—pharynx cancer	0.000242	0.000412	CbGeAlD
Crizotinib—MAPK7—Innate Immune System—EGFR—pharynx cancer	0.000188	0.000456	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—CDH1—pharynx cancer	0.000188	0.000454	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—CDH1—pharynx cancer	0.000188	0.000454	CbGpPWpGaD
Crizotinib—JAK2—Chromatin modifying enzymes—CCND1—pharynx cancer	0.000187	0.000452	CbGpPWpGaD
Crizotinib—JAK2—Downstream signal transduction—EGFR—pharynx cancer	0.000186	0.00045	CbGpPWpGaD
Crizotinib—JAK2—Signaling by FGFR—EGFR—pharynx cancer	0.000185	0.000448	CbGpPWpGaD
Crizotinib—JAK2—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000185	0.000448	CbGpPWpGaD
Crizotinib—LYN—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000184	0.000446	CbGpPWpGaD
Crizotinib—JAK2—Signaling by ERBB2—EGFR—pharynx cancer	0.000184	0.000446	CbGpPWpGaD
Crizotinib—JAK2—DAP12 signaling—EGFR—pharynx cancer	0.000183	0.000443	CbGpPWpGaD
Crizotinib—LCK—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000181	0.000438	CbGpPWpGaD
Crizotinib—JAK2—Factors involved in megakaryocyte development and platelet production—TP53—pharynx cancer	0.000179	0.000432	CbGpPWpGaD
Crizotinib—EPHA2—Developmental Biology—EGFR—pharynx cancer	0.000178	0.00043	CbGpPWpGaD
Crizotinib—LCK—Disease—B4GALT5—pharynx cancer	0.000177	0.000428	CbGpPWpGaD
Crizotinib—ABL1—Integrated Breast Cancer Pathway—TP53—pharynx cancer	0.000175	0.000423	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD79A—pharynx cancer	0.000174	0.000421	CbGpPWpGaD
Crizotinib—CDK7—Cell Cycle—CCND1—pharynx cancer	0.000174	0.00042	CbGpPWpGaD
Crizotinib—LCK—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.000173	0.000419	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD79A—pharynx cancer	0.000173	0.000419	CbGpPWpGaD
Crizotinib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000173	0.000418	CbGpPWpGaD
Crizotinib—JAK2—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000172	0.000417	CbGpPWpGaD
Crizotinib—JAK2—DAP12 interactions—EGFR—pharynx cancer	0.000172	0.000417	CbGpPWpGaD
Crizotinib—JAK2—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000172	0.000417	CbGpPWpGaD
Crizotinib—TEK—Hemostasis—TP53—pharynx cancer	0.000172	0.000417	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD79A—pharynx cancer	0.000172	0.000415	CbGpPWpGaD
Crizotinib—JAK2—Signaling by EGFR—EGFR—pharynx cancer	0.000171	0.000413	CbGpPWpGaD
Crizotinib—LCK—Signaling by ERBB4—EGFR—pharynx cancer	0.000171	0.000413	CbGpPWpGaD
Crizotinib—LYN—B Cell Activation—EGFR—pharynx cancer	0.000171	0.000413	CbGpPWpGaD
Crizotinib—SRC—Senescence and Autophagy in Cancer—TP53—pharynx cancer	0.00017	0.000412	CbGpPWpGaD
Crizotinib—JAK2—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000169	0.00041	CbGpPWpGaD
Crizotinib—ABCB1—lymph node—pharynx cancer	0.000169	0.000288	CbGeAlD
Crizotinib—JAK2—Signaling by PDGF—EGFR—pharynx cancer	0.000169	0.000408	CbGpPWpGaD
Crizotinib—LCK—Downstream signal transduction—EGFR—pharynx cancer	0.000163	0.000394	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD79A—pharynx cancer	0.000163	0.000394	CbGpPWpGaD
Crizotinib—LCK—Signaling by FGFR—EGFR—pharynx cancer	0.000162	0.000392	CbGpPWpGaD
Crizotinib—LCK—Signaling by ERBB2—EGFR—pharynx cancer	0.000161	0.00039	CbGpPWpGaD
Crizotinib—SRC—Focal Adhesion—CCND1—pharynx cancer	0.000161	0.00039	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—CCND1—pharynx cancer	0.000161	0.000389	CbGpPWpGaD
Crizotinib—LCK—DAP12 signaling—EGFR—pharynx cancer	0.000161	0.000388	CbGpPWpGaD
Crizotinib—SRC—Signaling by SCF-KIT—EGFR—pharynx cancer	0.00016	0.000388	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.00016	0.000388	CbGpPWpGaD
Crizotinib—IRAK1—Signaling by NGF—EGFR—pharynx cancer	0.00016	0.000386	CbGpPWpGaD
Crizotinib—TXK—Immune System—EGFR—pharynx cancer	0.000159	0.000385	CbGpPWpGaD
Crizotinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000158	0.000383	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD79A—pharynx cancer	0.000158	0.000382	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—CDH1—pharynx cancer	0.000158	0.000381	CbGpPWpGaD
Crizotinib—SRC—Disease—B4GALT5—pharynx cancer	0.000157	0.000379	CbGpPWpGaD
Crizotinib—TYK2—Signaling by NGF—EGFR—pharynx cancer	0.000155	0.000375	CbGpPWpGaD
Crizotinib—AURKA—Cell Cycle—TP53—pharynx cancer	0.000155	0.000375	CbGpPWpGaD
Crizotinib—PTK2—Axon guidance—EGFR—pharynx cancer	0.000154	0.000374	CbGpPWpGaD
Crizotinib—TBK1—Innate Immune System—EGFR—pharynx cancer	0.000154	0.000372	CbGpPWpGaD
Crizotinib—TBK1—Immune System—CDH1—pharynx cancer	0.000153	0.000371	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD79A—pharynx cancer	0.000153	0.00037	CbGpPWpGaD
Crizotinib—JAK2—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000153	0.00037	CbGpPWpGaD
Crizotinib—YES1—Axon guidance—EGFR—pharynx cancer	0.000152	0.000369	CbGpPWpGaD
Crizotinib—LCK—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000151	0.000365	CbGpPWpGaD
Crizotinib—LCK—DAP12 interactions—EGFR—pharynx cancer	0.000151	0.000365	CbGpPWpGaD
Crizotinib—LCK—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000151	0.000365	CbGpPWpGaD
Crizotinib—LCK—Signaling by EGFR—EGFR—pharynx cancer	0.00015	0.000362	CbGpPWpGaD
Crizotinib—PLK4—Cell Cycle—TP53—pharynx cancer	0.000149	0.00036	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—EGFR—pharynx cancer	0.000148	0.000359	CbGpPWpGaD
Crizotinib—LCK—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000148	0.000359	CbGpPWpGaD
Crizotinib—LCK—Signaling by PDGF—EGFR—pharynx cancer	0.000148	0.000357	CbGpPWpGaD
Crizotinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pharynx cancer	0.000148	0.000357	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—CDH1—pharynx cancer	0.000147	0.000356	CbGpPWpGaD
Crizotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000145	0.000351	CbGpPWpGaD
Crizotinib—SRC—Downstream signal transduction—EGFR—pharynx cancer	0.000144	0.000349	CbGpPWpGaD
Crizotinib—SRC—Signaling by FGFR—EGFR—pharynx cancer	0.000144	0.000347	CbGpPWpGaD
Crizotinib—SRC—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000144	0.000347	CbGpPWpGaD
Crizotinib—SRC—Signaling by ERBB2—EGFR—pharynx cancer	0.000143	0.000346	CbGpPWpGaD
Crizotinib—SRC—TGF-beta Signaling Pathway—TP53—pharynx cancer	0.000142	0.000343	CbGpPWpGaD
Crizotinib—TYK2—Axon guidance—EGFR—pharynx cancer	0.00014	0.000339	CbGpPWpGaD
Crizotinib—LCK—B Cell Activation—EGFR—pharynx cancer	0.00014	0.000338	CbGpPWpGaD
Crizotinib—JAK3—Immune System—CDH1—pharynx cancer	0.000139	0.000335	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CNDP2—pharynx cancer	0.000136	0.000328	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—CCND1—pharynx cancer	0.000135	0.000326	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—CCND1—pharynx cancer	0.000135	0.000326	CbGpPWpGaD
Crizotinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000134	0.000324	CbGpPWpGaD
Crizotinib—SRC—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000134	0.000323	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR—EGFR—pharynx cancer	0.000133	0.000321	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000131	0.000318	CbGpPWpGaD
Crizotinib—SRC—Signaling by PDGF—EGFR—pharynx cancer	0.000131	0.000316	CbGpPWpGaD
Crizotinib—JAK3—Hemostasis—TP53—pharynx cancer	0.00013	0.000314	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD79A—pharynx cancer	0.000128	0.00031	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—CCND1—pharynx cancer	0.000128	0.000309	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD79A—pharynx cancer	0.000127	0.000308	CbGpPWpGaD
Crizotinib—SRC—Focal Adhesion—EGFR—pharynx cancer	0.000126	0.000306	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—EGFR—pharynx cancer	0.000126	0.000305	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000126	0.000304	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—TP53—pharynx cancer	0.000125	0.000302	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—EGFR—pharynx cancer	0.000124	0.0003	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CDH1—pharynx cancer	0.000124	0.000299	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ADH7—pharynx cancer	0.000123	0.000297	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CDH1—pharynx cancer	0.000122	0.000295	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—EGFR—pharynx cancer	0.000121	0.000292	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—EGFR—pharynx cancer	0.00012	0.000291	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD79A—pharynx cancer	0.00012	0.00029	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—EGFR—pharynx cancer	0.000119	0.000288	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—EGFR—pharynx cancer	0.000119	0.000288	CbGpPWpGaD
Crizotinib—BLK—Immune System—CDH1—pharynx cancer	0.000119	0.000288	CbGpPWpGaD
Crizotinib—FGR—Immune System—CDH1—pharynx cancer	0.000118	0.000287	CbGpPWpGaD
Crizotinib—SRC—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000118	0.000287	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—CDH1—pharynx cancer	0.000118	0.000284	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—EGFR—pharynx cancer	0.000117	0.000284	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—CCND1—pharynx cancer	0.000117	0.000283	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—EGFR—pharynx cancer	0.000115	0.000277	CbGpPWpGaD
Crizotinib—CDK7—Cell Cycle—TP53—pharynx cancer	0.000114	0.000277	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—EGFR—pharynx cancer	0.000114	0.000275	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—EGFR—pharynx cancer	0.000113	0.000274	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—TP53—pharynx cancer	0.000111	0.000268	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—EGFR—pharynx cancer	0.00011	0.000267	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—EGFR—pharynx cancer	0.00011	0.000266	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—EGFR—pharynx cancer	0.00011	0.000266	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—EGFR—pharynx cancer	0.000109	0.000263	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ADH1B—pharynx cancer	0.000108	0.00026	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—EGFR—pharynx cancer	0.000106	0.000257	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—TP53—pharynx cancer	0.000106	0.000256	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—EGFR—pharynx cancer	0.000106	0.000256	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—EGFR—pharynx cancer	0.000106	0.000256	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000106	0.000256	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD79A—pharynx cancer	0.000105	0.000254	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—EGFR—pharynx cancer	0.000103	0.000249	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—B4GALT5—pharynx cancer	0.000103	0.000249	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CNDP2—pharynx cancer	0.000102	0.000248	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—CCND1—pharynx cancer	0.000102	0.000247	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—EGFR—pharynx cancer	0.0001	0.000243	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—EGFR—pharynx cancer	0.0001	0.000242	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—EGFR—pharynx cancer	9.74e-05	0.000236	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CDH1—pharynx cancer	9.7e-05	0.000235	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CDH1—pharynx cancer	9.64e-05	0.000233	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—EGFR—pharynx cancer	9.6e-05	0.000232	CbGpPWpGaD
Crizotinib—YES1—Immune System—CDH1—pharynx cancer	9.56e-05	0.000231	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	9.49e-05	0.00023	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD79A—pharynx cancer	9.29e-05	0.000225	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ADH7—pharynx cancer	9.25e-05	0.000224	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—CCND1—pharynx cancer	9.24e-05	0.000224	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—EGFR—pharynx cancer	9.22e-05	0.000223	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—EGFR—pharynx cancer	9.17e-05	0.000222	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—EGFR—pharynx cancer	9.11e-05	0.00022	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—EGFR—pharynx cancer	9.11e-05	0.00022	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TP53—pharynx cancer	9.08e-05	0.00022	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CDH1—pharynx cancer	9.07e-05	0.000219	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—CCND1—pharynx cancer	9.04e-05	0.000219	CbGpPWpGaD
Crizotinib—TBK1—Immune System—EGFR—pharynx cancer	8.97e-05	0.000217	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TP53—pharynx cancer	8.96e-05	0.000217	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TP53—pharynx cancer	8.88e-05	0.000215	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TP53—pharynx cancer	8.88e-05	0.000215	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—EGFR—pharynx cancer	8.87e-05	0.000215	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—EGFR—pharynx cancer	8.84e-05	0.000214	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CDH1—pharynx cancer	8.81e-05	0.000213	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—EGFR—pharynx cancer	8.6e-05	0.000208	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CDH1—pharynx cancer	8.53e-05	0.000206	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TP53—pharynx cancer	8.42e-05	0.000204	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—EGFR—pharynx cancer	8.24e-05	0.000199	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ADH1B—pharynx cancer	8.11e-05	0.000196	CbGpPWpGaD
Crizotinib—JAK3—Immune System—EGFR—pharynx cancer	8.11e-05	0.000196	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—EGFR—pharynx cancer	8.11e-05	0.000196	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—EGFR—pharynx cancer	8.07e-05	0.000195	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—EGFR—pharynx cancer	8.02e-05	0.000194	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—B4GALT5—pharynx cancer	7.76e-05	0.000188	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TP53—pharynx cancer	7.7e-05	0.000186	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—EGFR—pharynx cancer	7.59e-05	0.000184	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	7.44e-05	0.00018	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—EGFR—pharynx cancer	7.25e-05	0.000175	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—EGFR—pharynx cancer	7.23e-05	0.000175	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—EGFR—pharynx cancer	7.16e-05	0.000173	CbGpPWpGaD
Crizotinib—LYN—Immune System—CDH1—pharynx cancer	7.13e-05	0.000173	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—EGFR—pharynx cancer	7.13e-05	0.000172	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—EGFR—pharynx cancer	7.12e-05	0.000172	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CDH1—pharynx cancer	7.1e-05	0.000172	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—EGFR—pharynx cancer	7.1e-05	0.000172	CbGpPWpGaD
Crizotinib—CDK7—Disease—EGFR—pharynx cancer	6.99e-05	0.000169	CbGpPWpGaD
Crizotinib—BLK—Immune System—EGFR—pharynx cancer	6.95e-05	0.000168	CbGpPWpGaD
Crizotinib—FGR—Immune System—EGFR—pharynx cancer	6.93e-05	0.000168	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—EGFR—pharynx cancer	6.88e-05	0.000166	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—pharynx cancer	6.73e-05	0.000163	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—EGFR—pharynx cancer	6.7e-05	0.000162	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CCND1—pharynx cancer	6.68e-05	0.000162	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—pharynx cancer	6.68e-05	0.000162	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CDH1—pharynx cancer	6.67e-05	0.000161	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—pharynx cancer	6.65e-05	0.000161	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CNDP2—pharynx cancer	6.3e-05	0.000153	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	6.25e-05	0.000151	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—pharynx cancer	6.25e-05	0.000151	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—pharynx cancer	6.09e-05	0.000147	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—pharynx cancer	5.96e-05	0.000144	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CCND1—pharynx cancer	5.96e-05	0.000144	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EGFR—pharynx cancer	5.88e-05	0.000142	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CCND1—pharynx cancer	5.87e-05	0.000142	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EGFR—pharynx cancer	5.87e-05	0.000142	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDH1—pharynx cancer	5.84e-05	0.000141	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADH7—pharynx cancer	5.7e-05	0.000138	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—pharynx cancer	5.67e-05	0.000137	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—pharynx cancer	5.64e-05	0.000136	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—pharynx cancer	5.64e-05	0.000136	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCND1—pharynx cancer	5.62e-05	0.000136	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—pharynx cancer	5.59e-05	0.000135	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—pharynx cancer	5.47e-05	0.000132	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCND1—pharynx cancer	5.45e-05	0.000132	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—pharynx cancer	5.3e-05	0.000128	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—pharynx cancer	5.24e-05	0.000127	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—pharynx cancer	5.2e-05	0.000126	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDH1—pharynx cancer	5.17e-05	0.000125	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—pharynx cancer	5.15e-05	0.000125	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADH1B—pharynx cancer	5e-05	0.000121	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—pharynx cancer	4.99e-05	0.000121	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—pharynx cancer	4.85e-05	0.000117	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—B4GALT5—pharynx cancer	4.78e-05	0.000116	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—pharynx cancer	4.75e-05	0.000115	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCND1—pharynx cancer	4.67e-05	0.000113	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—pharynx cancer	4.67e-05	0.000113	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCND1—pharynx cancer	4.61e-05	0.000112	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—pharynx cancer	4.61e-05	0.000111	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—pharynx cancer	4.41e-05	0.000107	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—pharynx cancer	4.4e-05	0.000106	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCND1—pharynx cancer	4.37e-05	0.000106	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—pharynx cancer	4.27e-05	0.000103	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—pharynx cancer	4.27e-05	0.000103	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—pharynx cancer	4.24e-05	0.000103	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—pharynx cancer	4.17e-05	0.000101	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—pharynx cancer	4.15e-05	0.0001	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—pharynx cancer	3.92e-05	9.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—pharynx cancer	3.9e-05	9.44e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—pharynx cancer	3.87e-05	9.35e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—pharynx cancer	3.7e-05	8.95e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—pharynx cancer	3.67e-05	8.87e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—pharynx cancer	3.62e-05	8.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—pharynx cancer	3.6e-05	8.72e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—pharynx cancer	3.59e-05	8.68e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—pharynx cancer	3.44e-05	8.31e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—pharynx cancer	3.43e-05	8.3e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—pharynx cancer	3.42e-05	8.27e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—pharynx cancer	3.33e-05	8.05e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—pharynx cancer	3.22e-05	7.78e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—pharynx cancer	3.16e-05	7.64e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—pharynx cancer	3.08e-05	7.45e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—pharynx cancer	3.04e-05	7.35e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—pharynx cancer	3.03e-05	7.32e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—pharynx cancer	2.88e-05	6.97e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—pharynx cancer	2.82e-05	6.81e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—pharynx cancer	2.8e-05	6.76e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—pharynx cancer	2.79e-05	6.76e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—pharynx cancer	2.7e-05	6.52e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—pharynx cancer	2.52e-05	6.1e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—pharynx cancer	2.49e-05	6.03e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—pharynx cancer	2.26e-05	5.48e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—pharynx cancer	2.21e-05	5.35e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—pharynx cancer	2.12e-05	5.13e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—pharynx cancer	1.96e-05	4.73e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—pharynx cancer	1.86e-05	4.49e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—pharynx cancer	1.64e-05	3.97e-05	CbGpPWpGaD
